Clinical Trial Update: Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating granulocyte macrophage-colony stimulating factor (GM-CSF) and ipilimumab as therapy in metastatic malignant melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• GM-CSF (granulocyte-macrophage colony-stimulating factor)
• ipilimumab (ipilimumab)

Snippet

Sponsor: Lynn E. Spitler, MD | Conditions: Malignant Melanoma, Metastatic | Phase 2 | Status: COMPLETED